# US 10,117,931 B2 · Methods for treatment of age-related macular degeneration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,117,931 B2
- Document ID: US10117931B2
- Status: Granted
- Kind: B2
- Application number: 14/134,633
- Filed: 2013-12-19
- Published: 2014-05-01
- Granted: 2018-11-06
- Earliest claimed: 2009-04-28
- Assignees: Kameran Lashkari
- Applicants: Kameran Lashkari
- Inventors: Kameran Lashkari
- Web page: https://patentgrep.com/patent/US10117931B2

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/351: not condensed with another ring
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61K 31/69: Boron compounds
- A61P 27/02: Ophthalmic agents
- C07K 14/7158: {for chemokines}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- G01N 33/6866: {Interferon}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2333/4715: Cytokine-induced proteins
- G01N 2333/521: Chemokines
- G01N 2800/16: Ophthalmology
- G01N 2800/50: Determining the risk of developing a disease
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention provides compositions and methods of predicting a subject's risk of developing age-related macular degeneration (AMD) and methods of treating, delaying, or preventing the development and progression of AMD.

## Claims

### Claim 1

A method comprising:
treating dry AMD (age-related macular degeneration) in a subject by administering to said subject a composition that inhibits an activity of IP-10 (interferon-gamma inducible protein-10) by reducing a level of IP-10 present in the subject after administration of the composition relative to a level of IP-10 present in the subject prior to the administration of the composition, wherein the composition comprises one of a solubilized receptor that binds circulating IP-10, a CXCR3 receptor antagonist or a neutralizing antibody.

### Claim 2 (depends on 1)

The method of claim 1, wherein said composition is administered intravenously, subcutaneously, or orally.

### Claim 3 (depends on 1)

The method of claim 1, wherein said composition is administered locally, topically, intraocularly, periburlbarly, or intravitreally.

### Claim 4 (depends on 1)

The method of claim 1, wherein when the composition comprises the CXCR3 receptor antagonist, the CXCR3 receptor antagonist is selected from the group consisting of NSC651016, LMP420, AZD3778, T0906487, AMG487, TAK779, and NBI-74330.

### Claim 5 (depends on 1)

The method of claim 1, wherein said method further comprises administering to said subject a second composition that inhibits an activity of eotaxin.

### Claim 6

A method, comprising:
treating dry AMD (age-related macular degeneration) in a subject having antibodies at or above an age-related eye disease study (AREDS) stage one by administering to said subject a composition that inhibits an activity of IP-10 (interferon-gamma inducible protein-10) by reducing a level of IP-10 present in the subject after administration of the composition relative to a level of IP-10 present in the subject prior to the administration of the composition wherein the composition comprises one of a solubilized receptor that binds circulating IP-10, a CXCR3 receptor antagonist or a neutralizing antibody.